Distributors of prescription medicines - including Deferasirox - carry real pharmacovigilance (PV) responsibilities. These are increasingly enforced by regulators and embedded in supply agreements. This primer outlines the essentials.
1. What is Pharmacovigilance? #
Pharmacovigilance is the systematic collection, evaluation and response to adverse drug reactions and other drug-safety information. Every marketed medicine has a lifecycle PV obligation.
2. Distributor Responsibilities #
- Capture suspected adverse events reported by healthcare professionals / patients / pharmacists
- Forward Individual Case Safety Reports (ICSRs) to manufacturer / MAH within agreed timeframes
- Submit reports to local pharmacovigilance authority where required
- Maintain PV-trained staff with documented training records
- Participate in Periodic Safety Update Reports (PSUR) data collection
- Implement risk-minimisation measures (patient cards, HCP education)
- Maintain traceability from distribution to patient level where required
3. Key Timelines (Typical) #
| Event Type | Reporting Timeline |
|---|---|
| Serious unexpected adverse reaction | Within 15 calendar days |
| Fatal or life-threatening | Expedited (often 7-15 calendar days depending on market) |
| Non-serious adverse reaction | Typically periodic / within 90 days |
| Urgent safety concern | Immediate (same business day) |
4. PV Agreement #
Every distributor should have a signed PV Agreement with the manufacturer or MAH defining: case forwarding process, translation responsibilities, local-authority reporting, PSUR contribution, risk-minimisation implementation and audit rights.
5. Common Gaps #
- Untrained front-line staff missing reportable events
- Delayed forwarding of cases to MAH
- Missed local-authority submissions where distributor holds direct obligation
- No documented PV training records at audit
6. Taj Pharma PV Interface #
We operate a documented PV system with ICSR intake, PSUR contribution and risk-management. Distributor PV Agreements are signed on distribution appointment. Contact pharmacovigilance@tajpharma.com.